41339-61-1

Basic information

• Product Name: 2-(5-BENZYLOXY-1H-INDOL-3-YL)-ETHANOL
• Synonyms: 5-BENZYLOXY-3-(2-HYDROXYETHYL)INDOLE;5-BENZYLOXYTRYPTOPHOL;2-(5-BENZYLOXY-1H-INDOL-3-YL)-ETHANOL
• CAS NO: 41339-61-1
• Molecular Formula: C₁₇H₁₇NO₂
• Molecular Weight: 267.32
• Mol File: 41339-61-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(5-BENZYLOXY-1H-INDOL-3-YL)-ETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-BENZYLOXY-1H-INDOL-3-YL)-ETHANOL(41339-61-1)
• EPA Substance Registry System: 2-(5-BENZYLOXY-1H-INDOL-3-YL)-ETHANOL(41339-61-1)

Safety Data

• Hazardous Substances Data: 41339-61-1(Hazardous Substances Data)

Usage

Ethanol derivative

Structure The compound has an ethanol (C2H5OH) functional group as its base structure.

Benzyl and indolyl groups

Attached groups A benzyl group (C6H5CH2-) and an indolyl group (C8H6N-) are attached to the carbon chain of the ethanol derivative.

Indole derivatives

Family 2-(5-Benzyloxy-1H-indol-3-yl)-ethanol belongs to the family of indole derivatives, which are compounds containing an indole ring.

Natural products and pharmaceuticals

Occurrence Indole derivatives are widely found in various natural products and pharmaceuticals, indicating the prevalence and importance of this class of compounds.

Potential pharmacological activities

Biological activity Due to its structural features, 2-(5-Benzyloxy-1H-indol-3-yl)-ethanol may exhibit pharmacological activities, making it a candidate for further research and development.

Upstream product

• 22424-61-9 2-[5-(benzyloxy)-1H-indol-3-yl]-2-oxoacetyl chloride 
• 62995-58-8 (5-benzyloxy-1H-indol-3-yl)oxoacetic acid methyl ester 
• 1453-97-0 5-benzyloxygramine 
• 1191-99-7 2,3-dihydro-2H-furan 
• 52068-30-1 4-benzyloxyphenylhydrazine hydrochloride 
• 4382-53-0 2-(5-benzyloxy-1H-indol-3-yl)acetic acid 

Downstream Products

• 1252592-48-5 5-(benzyloxy)-3-(2-bromoethyl)-1-methyl-1H-indole 
• 1252592-49-6 4-({2-[5-(benzyloxy)-1-methyl-1H-indol-3-yl]ethyl}(4H-1,2,4-triazol-4-yl)amino)benzonitrile 
• 1252592-50-9 4-{[2-(5-hydroxy-1-methyl-1H-indol-3-yl)ethyl](4H-1,2,4-triazol-4-yl)amino}benzonitrile 
• 1252592-51-0 3-{2-[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]ethyl}-1-methyl-1H-indol-5-yl sulfamate 
• 132148-51-7 5-(benzyloxy)-3-(2-bromoethyl)-1H-indole 
• 135873-13-1 1-Ethyl-1,3,4,9-tetrahydro-6-(phenylmethoxy)pyrano[3,4-b]indole-1-acetic acid methyl ester 
• 42821-29-4 6-benzyloxy-1,1-dimethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indole 
• 135873-16-4 (6-benzyloxy-1-methyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid ethyl ester 
• 42820-54-2 2-(6-benzyloxy-1,9-dimethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-N,N-dimethyl-acetamide 
• 42820-44-0 (6-benzyloxy-1,9-dimethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid 
• 42820-91-7 [2-(6-benzyloxy-1,9-dimethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-ethyl]-dimethyl-amine 

Relevant articles and documents

AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS

The present invention provides azepino-indoles and other heterocycles and methods of using the compounds for treating brain disorders.

Bicyclic derivatives of the potent dual aromatase-steroid sulfatase inhibitor 2-bromo-4-{[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl} phenylsulfamate: Synthesis, SAR, crystal structure, and in vitro and in vivo activities

The design and synthesis of a series of bicyclic ring containing dual aromatase-sulfatase inhibitors (DASIs) based on the aromatase inhibitor (AI) 4-[(4-bromobenzyl)(4H-1,2,4-triazol-4-yl)amino] benzonitrile are reported. Biological evaluation with JEG-3 cells revealed structure-activity relationships. The X-ray crystal structure of sulfamate 23 was determined, and selected compounds were docked into the aromatase and steroid sulfatase (STS) crystal structures. In the sulfamate-containing series, compounds containing a naphthalene ring are both the most potent AI (39, IC50AROM=0.25 nm) and the best STS inhibitor (31, IC50STS=26 nm). The most promising DASI is 39 (IC50AROM= 0.25 nm, IC50STS=205 nm), and this was evaluated orally in vivo at 10 mgkg-1, showing potent inhibition of aromatase (93%) and STS (93%) after 3 h. Potent aromatase and STS inhibition can thus be achieved with a DASI containing a bicyclic ring system; development of such a DASI could provide an attractive new option for the treatment of hormone-dependent breast cancer.

NEW IMIDAZOLE DERIVATIVES, PRODUCTION THEREOF, AND USES THEREOF AS MEDICINES

Imidazole derivatives of general formula (I) and pharmacologically acceptable salts thereof, wherein m and n are each an integer of 1 to 3, R1 is hydrogen or ester residue, and the indoline skeleton may be substituted by at least one member selected from a C1 to C10 alkyl group and a C1 to C15 alkoxy group. These compounds have excellent pharmacological actions such as inhibition of lipid peroxide formation, inhibition of platelet agglutination caused by thromboxane A2 synthetase inhibition, and vasodilation. Thus they are effectively used in preventing or treating asthma, thrombosis, embolism, arteriosclerosis, hypertension, hyperlipemia, cerebral apoplexy, cardiac infarction, dementia, diabetes, etc.